We’re thrilled to share that the FDA has approved our transition to a new solid form of #buntanetap for our clinical trials targeting #Alzheimers and #Parkinsons diseases! $ANVS
Read more: globenewswire.com/news-release/2…
Annovis Bio
@AnnovisBio
Developing RNA-targeted therapies for Alzheimer's disease (AD) and Parkinson's disease (PD). Lead candidate buntanetap in Phase 3 trials. NYSE: ANVS
